A Japanese randomized controlled trial evaluating the safety of Vonoprazan over 5 years for gastroesophageal reflux disease (GERD) maintenance therapy, reported no increased risk of neoplastic changes and enterochromaffin‐like (ECL) hyperplasia, although elevated serum gastrin, and higher incidence of parietal cell and foveolar hyperplasia were noted compared to PPI.1 Here, GAST is linked to gastroesophageal reflux disease.